However, further research is needed to determine if FOXA1 Class 2 mutations emerge spontaneously during natural disease progression—such as in de novo metastatic tumors—or are instead induced by the selective pressure of androgen/AR blockade. This evidence concerns the gene FOXA1 and metastatic neoplasm.